Daiichi Sankyo Company, Limited (TYO:4568)
Japan
· Delayed Price · Currency is JPY 3,547.00
-60.00 (-1.66%)
May 9, 2025, 3:30 PM JST
Daiichi Sankyo Company Employees
Daiichi Sankyo Company had 18,726 employees as of March 31, 2024. The number of employees increased by 1,291 or 7.40% compared to the previous year.
Employees
18,726
Change (1Y)
1,291
Growth (1Y)
7.40%
Revenue / Employee
100.73M JPY
Profits / Employee
15.79M JPY
Market Cap
6,621.02B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Chugai Pharmaceutical | 5,026 |
| Takeda Pharmaceutical Company | 49,281 |
| HOYA Corporation | 35,702 |
| Otsuka Holdings | 35,338 |
| Astellas Pharma | 14,754 |
| Olympus | 28,838 |
| Shionogi & | 4,959 |
| Sysmex | 10,042 |
Daiichi Sankyo Company News
- 2 days ago - ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery showed statistically significant and clinically meaningful improvement in pathologic complete response in high-risk HER2-positive early-stage breast cancer in DESTINY-Breast11 - Benzinga
- 2 days ago - ENHERTU® Followed by THP Before Surgery Showed Statistically Significant and Clinically Meaningful Improvement in Pathologic Complete Response in Patients With High-Risk HER2 Positive Early-Stage Breast Cancer in DESTINY-Breast11 Phase 3 Trial - Benzinga
- 11 days ago - Approaching the business with a 'patient-centric mindset': Daiichi Sankyo CEO - CNBC
- 13 days ago - Daiichi Sankyo Company, Limited (DSKYF) FY2024 Earnings Call Transcript - Seeking Alpha
- 14 days ago - Daiichi Sankyo rises on share buyback plan - Seeking Alpha
- 14 days ago - Daiichi Sankyo repors FY results - Seeking Alpha
- 18 days ago - ENHERTU® Plus Pertuzumab Demonstrated Highly Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival Versus THP as First-Line Therapy for Patients with HER2 Positive Metastatic Breast Cancer - Benzinga
- 4 weeks ago - Daiichi Sankyo: Good Diversification Tool For U.S. Investors - Seeking Alpha